ArticleJournal of virology2003
Application of chimeric feline foamy virus-based retroviral vectors for the induction of antiviral immunity in cats.
Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- PFV Tas protein recruits hnRNPF to promote the splicing of tas/bet pre-mRNA.Cell & bioscience · 2026Article
- Seroprevalence of Feline Foamy Virus in Domestic Cats in Poland.Journal of veterinary research · 2021Article
- Review
- Article
- Replacement of feline foamy virus bet by feline immunodeficiency virus vif yields replicative virus with novel vaccine candidate potential.Retrovirology · 2018Article
- Role of the single deaminase domain APOBEC3A in virus restriction, retrotransposition, DNA damage and cancer.The Journal of general virology · 2016Review
- Replication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy.PloS one · 2015Article
- Identification of novel, highly expressed retroviral microRNAs in cells infected by bovine foamy virus.Journal of virology · 2014Article
- Lentivirus restriction by diverse primate APOBEC3A proteins.Virology · 2013Article
- Review
- Immunisation with foamy virus Bet fusion proteins as novel strategy for HIV-1 epitope delivery.Immunologic research · 2013Article
- Immunising with the transmembrane envelope proteins of different retroviruses including HIV-1: a comparative study.Human vaccines & immunotherapeutics · 2013Review
- Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.Vaccine · 2008Review
- Construction and characterization of efficient, stable and safe replication-deficient foamy virus vectors.Gene therapy · 2007Article
- FIP: a novel approach to vaccination. Proceedings from the 2nd International FCoV/FIP Symposium, Glasgow, 4-7 August 2002.Journal of feline medicine and surgery · 2004Article
- Kinetics and characteristics of replication-competent revertants derived from self-inactivating foamy virus vectors.Gene therapy · 2004Article
- Potential of zoonotic transmission of non-primate foamy viruses to humans.Journal of veterinary medicine. B, Infectious diseases and veterinary public health · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to define the potential and applicability of replication-competent foamy virus-based vaccine vectors, recombinant feline foamy virus (FFV) vectors encoding defined segments of the feline calicivirus (FCV) capsid protein E domain were constructed. In cell cultures, these FFV-FCV vectors efficiently transduced and expressed a hybrid fusion protein consisting of the essential FFV Bet protein and the attached FCV E domains. The stability of the vectors in vitro was inversely correlated to the size of the heterologous insert. The deletion of a part of the FFV U3 sequence in these FFV-FCV vectors did not interfere with replication and titer in cell cultures but increased the genetic stability of the hybrid vectors. Selected chimeric vectors were injected into immunocompetent cats and persisted in the transduced host concomitant with a strong and specific humoral immune response against vector components. In a substantial number of cats, antibodies directed against the FCV E domain were induced by the FFV-FCV vectors, but no FCV-neutralizing activities were detectable in vitro. When the vaccinated cats were challenged with a high-titer FCV dose, sterile immunity was not induced by any of the hybrid FFV-FCV vectors. However, the FFV-FCV vector with a truncated U3 region of the long terminal repeat promoter significantly reduced the duration of FCV shedding after challenge and suppressed the appearance of FCV-specific ulcers. Possible mechanisms contributing to the partial protection will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.